What is the price-to-earnings ratio of Medigene?
The price-earnings ratio of Medigene is currently 2.92.
Medigene P/S 2024
Medigene P/S
2.92
Medigene Dividend yield
Ticker
MDG1.DE
ISIN
DE000A1X3W00
WKN
A1X3W0
As of Jun 8, 2024, Medigene's P/S ratio stood at 2.92, a -57.93% change from the 6.94 P/S ratio recorded in the previous year.
The Medigene P/S history
Medigene Aktienanalyse
What does Medigene do?
Medigene AG is a biopharmaceutical company based in Martinsried near Munich, specializing in the development of immunotherapies for the treatment of cancer and other serious diseases. The company was founded in 1994 and has been listed on the Frankfurt Stock Exchange since 2000. Medigene is one of the leading companies in the field of immunotherapy and focuses on innovative biotechnological research and development to contribute to new forms of therapy for patients worldwide. The company is divided into three business areas: immunotherapies, clinical development, and diagnostics. In the field of immunotherapies, Medigene invests in the development of immune cells that can recognize and effectively fight cancer cells. One of the main cell therapy products is T-cell receptor (TCR) therapies that specifically target the points of attack of T cells against cancer cells. Medigene takes a holistic approach and develops both autologous and allogeneic cell therapies tailored to the specific needs of each patient. Medigene is involved in numerous clinical trials to develop new therapies for a variety of diseases. The company's clinical developments target various types of cancer, including leukemia, skin cancer, lung cancer, prostate cancer, and ovarian carcinomas, as well as autoimmune diseases such as multiple sclerosis. In the diagnostics field, Medigene develops tests for the early detection of cancer and other diseases. The focus is on blood tests that target specific markers for different types of cancer. These tests can help detect cancer at an early stage when it is most treatable. Medigene's business model aims to offer patients innovative and effective therapies for fighting cancer and other serious diseases. The company's model is based on the research and development of immunotherapies. Medigene closely collaborates with academic institutions and other companies to advance their research and development. Medigene's business model combines its own development work with partnerships with other companies. The company collaborates with a number of pharmaceutical manufacturers to bring its products to the market and make them accessible to patients worldwide. The Medigene AG was founded in 1994 by Prof. Dr. Dolores Schendel as Medigene Inc. in the USA. In 1996, the company was converted into a stock corporation and relocated to Germany. In 2000, it went public on the Frankfurt Stock Exchange. In the following years, Medigene continuously expanded its portfolio and expertise in the field of immunotherapies. In 2016, the company acquired Trianta Immunotherapies, specializing in TCR immunotherapies, and in 2017, it acquired Vigilant Biosciences Inc., a manufacturer of oral cancer tests. In conclusion, Medigene AG has established itself as a leading company in the field of immunotherapies and is dedicated to developing new treatment options for patients with cancer and other serious diseases. The company continuously invests in research and development to develop innovative cell therapies and make them accessible to patients worldwide. With its broad portfolio and holistic approach, Medigene has become an important company in the biotech industry that will continue to develop innovative drugs and diagnostics to fight cancer and other diseases in the future. Medigene ist eines der beliebtesten Unternehmen auf Eulerpool.com.P/S Details
Decoding Medigene's P/S Ratio
Medigene's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.
Year-to-Year Comparison
Comparing Medigene's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.
Impact on Investments
The P/S ratio is instrumental for investors evaluating Medigene's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.
Interpreting P/S Ratio Fluctuations
Variations in Medigene’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.
Frequently Asked Questions about Medigene Stock
How has the price-earnings ratio of Medigene changed compared to last year?
The price-to-earnings ratio of Medigene has increased by -57.93% fallen (meaning "decreased" or "dropped") compared to last year.
What consequences does a high price-earnings ratio have for investors?
A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.
What does a low price-earnings ratio mean?
A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.
Is the price-earnings ratio of Medigene high compared to other companies?
Yes, the price-to-earnings ratio of Medigene is high compared to other companies.
How does an increase in the price-earnings ratio of Medigene affect the company?
An increase in the price-earnings ratio of Medigene would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.
How does a reduction in the price-to-earnings ratio of Medigene affect the company?
A decrease in the price-earnings ratio of Medigene would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.
What are some factors that influence the price-earnings ratio of Medigene?
Some factors that influence the price-earnings ratio of Medigene are the company's growth, financial position, industry development, and the overall economic situation.
How much dividend does Medigene pay?
Over the past 12 months, Medigene paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Medigene is expected to pay a dividend of 0 EUR.
What is the dividend yield of Medigene?
The current dividend yield of Medigene is .
When does Medigene pay dividends?
Medigene pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Medigene?
Medigene paid dividends every year for the past 0 years.
What is the dividend of Medigene?
For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.
In which sector is Medigene located?
Medigene is assigned to the 'Health' sector.
Wann musste ich die Aktien von Medigene kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Medigene from 6/8/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 6/8/2024.
When did Medigene pay the last dividend?
The last dividend was paid out on 6/8/2024.
What was the dividend of Medigene in the year 2023?
In the year 2023, Medigene distributed 0 EUR as dividends.
In which currency does Medigene pay out the dividend?
The dividends of Medigene are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The Medigene stock can be added to a savings plan with the following providers: Trade Republic
Andere Kennzahlen von Medigene
Our stock analysis for Medigene Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Medigene Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
